Jane Street’s Summit Therapeutics SMMT Stock Holding History

Jane Street’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.96M	Sell	103,300 -171,000	-62%	-$2.77M	﹤0.01%	5130
2025 Q4	$4.8M	Sell	274,300 -100,200	-27%	-$1.89M	﹤0.01%	3290
2025 Q3	$7.74M	Buy	374,500 +80,900	+28%	+$1.96M	﹤0.01%	2763
2025 Q2	$6.25M	Buy	293,600 +119,200	+68%	+$2.72M	﹤0.01%	2717
2025 Q1	$3.36M	Sell	174,400 -237,400	-58%	-$4.76M	﹤0.01%	3547
2024 Q4	$7.35M	Sell	411,800 -272,500	-40%	-$5.28M	﹤0.01%	2195
2024 Q3	$15M	Buy	684,300 +630,800	+1,179%	+$8.82M	﹤0.01%	1505
2024 Q2	$417K	Buy	53,500 +40,200	+302%	+$217K	﹤0.01%	7311
2024 Q1	$55.1K	Buy	+13,300	New	+$52.9K	﹤0.01%	8718
2023 Q3	–	Sell	-15,500	Closed	-$38.9K	–	9325
2023 Q2	$38.9K	Sell	15,500 -30,500	-66%	-$55.7K	﹤0.01%	8262
2023 Q1	$80.5K	Sell	46,000 -117,400	-72%	-$320K	﹤0.01%	8314
2022 Q4	$694K	Buy	+163,400	New	+$297K	﹤0.01%	5588

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jane Street's SMMT Position: Q3 2025 in Review

Jane Street sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 249,710 shares — an estimated $6.06M sold.

Jane Street first reported a position in SMMT in Q4 2021 and held it in 12 quarters. The position peaked at $7.69M in Q3 2024. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

Jane Street reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
Jane Street sold 249,710 Summit Therapeutics shares in Q3 2025, an estimated $6.06M.
Jane Street first reported a position in Summit Therapeutics in Q4 2021 and held it in 12 quarters.
Jane Street's Summit Therapeutics position peaked at $7.69M in Q3 2024.
232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Jane Street's 13F filing for Q3 2025, filed 14 Nov 2025.